Investment Strategy

The investment seeks long-term capital appreciation. The fund invests at least 80% of its assets in the stocks of companies principally engaged in the development, production, or distribution of products and services related to the health care industry. These companies include, among others, pharmaceutical firms, medical supply companies, and businesses that operate hospitals and other health care facilities. The adviser may also consider companies engaged in medical, diagnostic, biochemical, and other research and development activities. The fund may invest up to 50% of its assets in foreign stocks. It is non-diversified.



Ticker:
VGHCX
Share Class:
Inv
CUSIP:
921908307
Inception Date:
05/23/1984


Investment Expenses, Sales Charges, and Fees

Annual Operating Expense

Net Expense Ratio: 0.35%


Average Annual Total Returns

All average annual total returns are reported net of all fees and as of the end of the last quarter. Past performance does not guarantee future results.


Year 1 3 5 10 Since Inception
(05/23/1984)
Total Returns
-5.74%
2.16%
8.36%
6.34%
14.76%

Impact of Expenses and Fees

The table below assumes the investor invests $10,000 on the first day of year one and that the original investment earns a continuous 5% return. In addition, it assumes the investor reinvests all earnings, and makes no additional contributions. The 5% rate of return is hypothetical and used only to illustrate the respective impacts of different fee amounts on each investment. It is not intended to predict future investment returns.

Calculations are done by the 403bCompare site in an effort to provide a standardized comparison of the impact of all fees associated with an investment option. This includes all required 403(b) product-level fees, and investment-level fees. For more information on fees or expenses associated with a 403(b) product or investment option, please refer fees located in Help & Resources .


If Shares are Redeemed
End of year
1
5
10
15
20
Total Fees and Charges
$134
$703
$1,495
$2,399
$3,440
If Shares are Not Redeemed
End of year
1
5
10
15
20
Total Fees and Charges
$134
$703
$1,495
$2,399
$3,440